Pages that link to "Q35751085"

The following pages link to Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab (Q35751085):

Displaying 48 items.

• European evidence based consensus on the diagnosis and management of Crohn's disease: special situations (Q22242050) (← links)
• Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update (Q26994776) (← links)
• Infliximab-Related Infusion Reactions: Systematic Review (Q27013835) (← links)
• Cystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab (Q33798912) (← links)
• The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations (Q34152778) (← links)
• Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease (Q34499843) (← links)
• Infliximab therapy in pediatric Crohn's disease: a review (Q35026358) (← links)
• Inflammatory bowel disease associated arthropathy (Q35680638) (← links)
• Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease (Q35954116) (← links)
• Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-α (Q36231590) (← links)
• Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins (Q36269608) (← links)
• Managing complicated Crohn's disease in children and adolescents (Q36331225) (← links)
• Infliximab therapy in children and adolescents with inflammatory bowel disease (Q36903742) (← links)
• Infliximab therapy for pediatric Crohn's disease (Q37012073) (← links)
• Short-term response to adalimumab in childhood inflammatory bowel disease (Q37212946) (← links)
• Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases. (Q37535680) (← links)
• Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease (Q37609746) (← links)
• Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. (Q37690479) (← links)
• Antitumor necrosis factor treatment for pediatric inflammatory bowel disease (Q37936394) (← links)
• Pediatric ulcerative colitis: current treatment approaches including role of infliximab (Q38022238) (← links)
• Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis (Q38059422) (← links)
• Infliximab for the treatment of pediatric ulcerative colitis (Q38067127) (← links)
• Characterisation of aptamers for therapeutic studies (Q38089865) (← links)
• Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response (Q38118313) (← links)
• The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. (Q38129037) (← links)
• Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis (Q38166552) (← links)
• Safety of TNF inhibitors in adolescents and children (Q38193792) (← links)
• Anti-TNF therapeutics for the treatment of sarcoidosis (Q38271881) (← links)
• The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease (Q38568813) (← links)
• Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? (Q38631012) (← links)
• Human IgE-independent systemic anaphylaxis (Q38821527) (← links)
• Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer (Q38971107) (← links)
• Alternative Anaphylactic Routes: The Potential Role of Macrophages (Q39323741) (← links)
• Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review (Q39371316) (← links)
• Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach (Q39834984) (← links)
• Update on bioagent therapy in sarcoidosis (Q42415512) (← links)
• Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium (Q46469250) (← links)
• Infliximab treatment in a paediatric patient with ulcerative colitis, who developed acute pancreatitis due to azathioprine during follow-up (Q47145064) (← links)
• A survey of applications of biological products for drug interference of immunogenicity assays (Q47247174) (← links)
• Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease (Q48185411) (← links)
• Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease (Q49109368) (← links)
• Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab (Q50065301) (← links)
• Infliximab drug and antibody levels in patients with dermatological conditions. (Q50591592) (← links)
• What are the guidelines for using biologics in pediatric patients? (Q53129698) (← links)
• Immunogenicity, efficacy and adverse events of adalimumab in RA patients (Q79151701) (← links)
• [Infliximab therapy for inflammatory bowel disease: seven years on] (Q81468903) (← links)
• Demonstration of specific antibodies against infliximab induced during treatment of a patient with ankylosing spondylitis (Q81601968) (← links)
• Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease (Q82849348) (← links)